Lobe Sciences Ltd
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Phone Number
(949) 505-5623Website
www.lobesciences.comRevenue
<$5 MillionStock Symbol
LOBEFIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Lobe Sciences Ltd
Lobe Sciences Inc is a biopharmaceutical company dedicated to developing innovative treatments for rare chronic diseases, specifically targeting Chronic Cluster Headache and Sickle Cell Disease. Their key products include Conjugated Psilocin, a patented chemical entity for Chronic Cluster Headache, and Altemia, a medical food designed for patients with Sickle Cell Disease. The company aims to address the significant unmet medical needs associated with these debilitating conditions. Their intended clients include patients suffering from these rare diseases, particularly children affected by Sickle Cell Disease.Explore more
Lobe Sciences Ltd Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lobe Sciences Ltd your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Lobe Sciences Ltd recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Lobe Sciences Ltd launches new products
Congratulate Masked Content for being promoted to Masked Content at Lobe Sciences Ltd
Funding: Get notified immidiatlly once Lobe Sciences Ltd has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Lobe Sciences Ltd had a recent Job posting/layoffs
Lobe Sciences Ltd, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Lobe Sciences Ltd has recently received funding, and reach out quickly before it becomes old news!
Check out if Lobe Sciences Ltd is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Lobe Sciences Ltd as Masked Content
Find 2 more new buyers
Compare Similar Companies to Lobe Sciences Ltd
Compare insights from companies similar to Lobe Sciences Ltd, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lobe Sciences Ltd is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lobe Sciences Ltd is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lobe Sciences Ltd.
Lobe Sciences Ltd Tech Stack
A closer look at the technologies used by Lobe Sciences Ltd
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Lobe Sciences Ltd News & Media
Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth
Lobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial strategy during its next phase of growth.Mr. Yao brings over 25 years of experience across finance and biotech, with executive roles at companies such as Mountain Valley MD and global firms like Scotiabank and Morgan Stanley.His appointment marks a strategic shift to full-time financial leadership, aligning with Lobe's commitment toLobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
VANCOUVER, British Columbia & STUART, Fla.--(BUSINESS WIRE)--Lobe Sciences, Ltd. ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma, Inc. (“Alera” or “Alera Pharma”), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce that a second patent allowance for Conjugated Psilocin™ has been received. The patent application is entitled “Stable Psilocin Salts, Esters, and Conjugates and Uses ThereofLobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™
VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd ("Lobe" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce the appointment of Enclave Capital and Peak Asset Management (the “Bankers”) to begin the process of raising funds to advance the development of the Company’s patented innovative pharmaceutical candidate, Conjugated Psilocin™. Lobe previously
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Lobe Sciences Ltd
Sign Up For FreeTo access detailed company insights
Lobe Sciences Inc is a biopharmaceutical company dedicated to developing innovative treatments for rare chronic diseases, specifically targeting Chronic Cluster Headache and Sickle Cell Disease. Their key products include Conjugated Psilocin, a patented chemical entity for Chronic Cluster Headache, and Altemia, a medical food designed for patients... Read More
